These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 20702076

  • 1. Predictive factors for evaluation of response to fluticasone propionate/salmeterol combination in severe COPD.
    Tonnel AB, Tillie-Leblond I, Attali V, Bavelele Z, Lagrange O.
    Respir Med; 2011 Feb; 105(2):250-8. PubMed ID: 20702076
    [Abstract] [Full Text] [Related]

  • 2. Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease.
    Hoshino M, Ohtawa J.
    Respirology; 2011 Jan; 16(1):95-101. PubMed ID: 20920142
    [Abstract] [Full Text] [Related]

  • 3. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C.
    Respir Med; 2008 Aug; 102(8):1099-108. PubMed ID: 18614347
    [Abstract] [Full Text] [Related]

  • 4. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study.
    Jung KS, Park HY, Park SY, Kim SK, Kim YK, Shim JJ, Moon HS, Lee KH, Yoo JH, Lee SD, Korean Academy of Tuberculosis and Respiratory Diseases study group, Korea Chronic Obstructive Pulmonary Disease study group.
    Respir Med; 2012 Mar; 106(3):382-9. PubMed ID: 21975275
    [Abstract] [Full Text] [Related]

  • 5. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
    Kurashima K, Hara K, Yoneda K, Kanauchi T, Kagiyama N, Tokunaga D, Takayanagi N, Ubukata M, Sugita Y.
    Respirology; 2009 Mar; 14(2):239-44. PubMed ID: 19210650
    [Abstract] [Full Text] [Related]

  • 6. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD.
    Hanania NA, Crater GD, Morris AN, Emmett AH, O'Dell DM, Niewoehner DE.
    Respir Med; 2012 Jan; 106(1):91-101. PubMed ID: 22040533
    [Abstract] [Full Text] [Related]

  • 7. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
    Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P, TRISTSAN study group.
    Thorax; 2005 Apr; 60(4):301-4. PubMed ID: 15790985
    [Abstract] [Full Text] [Related]

  • 8. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study.
    Make B, Hanania NA, ZuWallack R, Kalberg C, Emmett A, Brown CP, Knobil K.
    Clin Ther; 2005 May; 27(5):531-42. PubMed ID: 15978302
    [Abstract] [Full Text] [Related]

  • 9. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
    Hagedorn C, Kässner F, Banik N, Ntampakas P, Fielder K.
    Respir Med; 2013 Apr; 107(4):542-9. PubMed ID: 23337300
    [Abstract] [Full Text] [Related]

  • 10. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD.
    Cazzola M, Andò F, Santus P, Ruggeri P, Di Marco F, Sanduzzi A, D'Amato M.
    Pulm Pharmacol Ther; 2007 Apr; 20(5):556-61. PubMed ID: 16914336
    [Abstract] [Full Text] [Related]

  • 11. Combination therapy in COPD: different response of COPD stages and predictivity of functional parameters.
    Terzano C, Petroianni A, Ricci A, Allegra L.
    Eur Rev Med Pharmacol Sci; 2005 Apr; 9(4):209-15. PubMed ID: 16128040
    [Abstract] [Full Text] [Related]

  • 12. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
    Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J, TORCH investigators.
    N Engl J Med; 2007 Feb 22; 356(8):775-89. PubMed ID: 17314337
    [Abstract] [Full Text] [Related]

  • 13. Combined salmeterol and fluticasone for COPD.
    Vassiliou V.
    Lancet; 2003 May 10; 361(9369):1651; author reply 1652-3. PubMed ID: 12747901
    [No Abstract] [Full Text] [Related]

  • 14. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
    Blanchette CM, Akazawa M, Dalal A, Simoni-Wastila L.
    Am J Geriatr Pharmacother; 2008 Aug 10; 6(3):138-46. PubMed ID: 18775388
    [Abstract] [Full Text] [Related]

  • 15. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.
    Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ.
    Thorax; 2008 Jul 10; 63(7):592-8. PubMed ID: 18245142
    [Abstract] [Full Text] [Related]

  • 16. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.
    Kardos P, Wencker M, Glaab T, Vogelmeier C.
    Am J Respir Crit Care Med; 2007 Jan 15; 175(2):144-9. PubMed ID: 17053207
    [Abstract] [Full Text] [Related]

  • 17. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
    Schermer TR, Albers JM, Verblackt HW, Costongs RJ, Westers P.
    Fam Pract; 2007 Apr 15; 24(2):181-8. PubMed ID: 17251178
    [Abstract] [Full Text] [Related]

  • 18. Association between CRHR1 polymorphism and improved lung function in response to inhaled corticosteroid in patients with COPD.
    Kim WJ, Sheen SS, Kim TH, Huh JW, Lee JH, Kim EK, Lee JH, Lee SM, Lee S, Lim SY, Shin TR, Yoon HI, Oh YM, Lee SD.
    Respirology; 2009 Mar 15; 14(2):260-3. PubMed ID: 19210659
    [Abstract] [Full Text] [Related]

  • 19. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
    Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, Creutzberg EC, COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study Group.
    Thorax; 2005 Jun 15; 60(6):480-7. PubMed ID: 15923248
    [Abstract] [Full Text] [Related]

  • 20. Effect of salmeterol/fluticasone propionate combination on airway hyper-responsiveness in patients with well-controlled asthma.
    Chanez P, Stallaert R, Reznikova E, Bloemen P, Adamek L, Joos G.
    Respir Med; 2010 Aug 15; 104(8):1101-9. PubMed ID: 20452196
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.